Enterprise Value
63.81M
Cash
124.3M
Avg Qtr Burn
-34.45M
Short % of Float
3.84%
Insider Ownership
8.38%
Institutional Own.
73.50%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Autoimmune disease, Essential tremor | Phase 3 Initiation | |
PRAX-562 Details Developmental and Epileptic Encephalopathy | Phase 2 Data readout | |
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Parkinson's disease | Phase 2 Data readout | |
PRAX-628 Details Epilepsy, Focal Onset Seizures | Phase 2 Initiation | |
PRAX-222 Details Developmental and Epileptic Encephalopathy | Phase 1/2 Data readout | |
PRAX-114 (GABAA receptor PAM) Details Major depressive disorder | Failed Discontinued | |
PRAX-114 (GABAA receptor PAM) Details Perimenopausal Depression | Failed Discontinued |